Educational Sessions

The transplant algorithm in lymphoma (1E)
Chairs: P. Dreger, Germany; M. Gomes da Silva, Portugal
  - High grade lymphoma: N. Milpied, France
  - Role of stem cell transplantation in patients with follicular lymphoma: S. Montoto, UK
  - Hodgkin disease: A. Sureda, Spain

The transplant algorithm in acute leukemia (2E)
Chairs: B. Savani, USA; J.E. Guimarães, Portugal
  - ALL: A. Nagler, Israel
  - De novo AML: A. Rambaldi, Italy
  - Secondary AML and MDS: N. Kroger, Germany

Transplant in elderly or fragile myeloma patients (3E)
Chairs: L. Garderet, France; F. Leal da Costa, Portugal
  - Transplant in patients with kidney dysfunction: J. Blade, Spain
  - Salvage transplant for relapse: G. Cook, UK
  - Transplant in elderly and frail myeloma patients: M. Mohty, France

Transplant in autoimmune disorders (4E)
Chairs: J. Snowden, UK; A. Botelho de Sousa, Portugal
  - Transplant for multiple sclerosis: R. Burt, USA
  - Transplant for Crohn's disease: M. Rovira, Spain
  - Transplant for lupus: D. Farge, France

The transplant algorithm in bone marrow failures (5E)
Chairs: M. Abecasis, Portugal; J. Passweg, Switzerland
  - Severe aplastic anemia: to transplant or not to transplant? A. Risitano, Italy
  - Inherited marrow failure disorders: C. Dufour, Italy
  - PNH: R. Peffault de Latour, France

Pharmacologic pre-transplant interventions to enhance disease control (6E)
Chairs: A. Bazarbarchi, Lebanon; C. Solano, Spain
  - Immune check-point inhibitors in lymphomas: M. Perales, USA
  - Bispecific antibodies in ALL: H. Einsele, Germany
  - Options in AML: J. Esteve, Spain

Pharmacologic post-transplant interventions to prevent relapse (7E)
Chairs: Jordi Esteve, Spain; Isabelina Ferreira, Portugal
  - FLT3 inhibitors: A. Bazarbachi, Lebanon
  - HDAC inhibitors: G. Bug, Germany
  - Hypomethylating agents: C. Craddock, UK

Chronic GVHD prevention and therapy (8E)
Chair: Antonio Campos, Portugal
  - Diagnosis and grading of chronic GVHD: S. Pavletic, USA
  - First line therapy of chronic GVHD: H. Greinix, Austria
  - Therapy of refractory chronic GVHD: A. Olivieri, Italy
Acute GVHD prevention and therapy (9E)
Chairs: G. Basak, Poland; N. Miranda, Portugal
  o Diagnosis and grading of acute GVHD: T. Rutuu, Finland
  o Pharmacologic prevention of acute GVHD: J. Perez Simon, Spain
  o Therapy of acute GVHD (first line and refractory): E. Holler, Germany

Late post-transplant complications (10E)
Chair: J.M. Moraleda, Spain
  o Bone complications: M. Arat, Turkey
  o Neuropsychological complications: A. Tichelli, Switzerland
  o Secondary malignancies: B. Savani, USA

Rare post-transplant complications (11E)
Chairs: Rafael Duarte, Spain; F. Campilho, Portugal
  o Transplant-related mortality: the elephant in the room: F.B. Petersen, USA
  o Cyclophosphamide and other related acute cardiac complications: R. Dulery, France
  o Pathophysiology and management of iron toxicity during and after transplantation: T. De Witte, The Netherlands

Drug and cell therapy for infections (12E)
Chairs: G. Teixeira, Portugal; R. de la Cámara, Spain
  o CMV management: P. Ljungman, Sweden
  o Multidrug-resistant bacteria in HSCT patients: D. Averbuch, Israel
  o Rare viruses (ex. HHV6, BKV, Adenovirus, etc): E. Brissot, France

HSCT for inherited diseases (13E)
Chairs: M. Gonzalez Vicent, Spain; M. Aljurf, Saudi-Arabia
  o Thalassemia: F. Locatelli, Italy
  o Sickle cell disease – what curative options do we have? S. Corbacioglu, Germany
  o HLH: A. Lankester, The Netherlands

Workshops

Results of haplo-identical transplantation (1W)
Chairs: N. Miranda, Portugal; J.L. Diez-Martin, Spain
  o In non-malignant hematological disease: X. Huang, China
  o In refractory AML: M. Mohty, France
  o In ALL: D. Blaise, France

Haplo-identical transplantation versus other donor sources (2W)
Chairs: I. Ferreira, Portugal; M. Rovira, Spain
  o AML: A.L. Ruggeri, France
  o Haplo-identical SCT in Hodgkin lymphoma: M. Kwon, Spain
  o ALL: J. Cornelissen, The Netherlands

Translational research in GVHD (3W)
Chairs: O. Penack, Germany; J. Lacerda, Portugal
  o The role of micro RNAs and kinases: R. Zeiser, Germany
  o Role of the endothelium: T. Luft, Germany
  o Role of invariant NKT cells: F. Malard, France

Fertility and sexuality – Joint Session with the Nurses Program (4W)
Chair: C. Pereira, Portugal
  o Fertility preservation in adults: M.M. Dolmans, Belgium
  o Management of sexual dysfunctioning: TBA
  o Fertility preservation in children: K. Jahnukainen, Finland
Challenging situations after allogeneic transplantation (5W)
Chairs: H. Schoemans, Belgium; C. Martins, Portugal
- Enteral nutrition after transplant: I. Yakoub-Agha, France
- Vascular access: S. Cesaro, Italy
- Transfusion support in case of refractoriness to platelets: H. Schrezenmeier, Germany

Management of some rare complications post-transplant (6W)
Chairs: T. Ruutu, Finland; A. Bermúdez, Spain
- TMA: E. Carreras, Spain
- IPS: A. Bergeron, France
- Poor graft function without rejection: A. Bacigalupo, Italy

Cellular therapy for GVHD modulation (7W)
Chairs: H. Greinix, Austria; J.A. Pérez Simon, Spain
- Mesenchymal cells: F. Sanchez-Guijo, Spain
- B Cells: J. Ritz, USA
- Regulatory T cells: J. Lacerda, Portugal

Questions in aplastic anemia (8W)
Chairs: J. Marsh, UK; M. Abecasis, Portugal
- Immunosuppressive therapy or SCT front line therapy: C. Dufour, Italy
- Eltrombopag: making stem cells great again: D. Townsley, USA
- SCT in older patients with SAA: TBA

Optimizing Quality of Life during and after Hematopoietic Cell Transplant (9W)
Chairs: F. Schulz-Kindermann; Germany, C. Pinho Vaz, Portugal
- Patient-reported outcomes measures: A. Barata, Spain
- QoL over time after transplantation: K. Syrjala, USA
- Interventions to improve QoL after transplantation: Z. Peric, Croatia

Monitoring prior and post-transplant (10W)
Chairs: J. Sanz, Spain; M. van den Brink, USA
- Strategies to enhance post-transplant immune reconstitution: M. van den Brink, USA
- MRD monitoring in AML and impact in the pre- and post-transplant settings: M. Heuser, Germany
- NGS-driven decisions in transplant for MDS: S. Ogawa, Japan

Plenary Sessions

Immunotherapy before and after transplantation (1P)
Chairs: A. Campos, Portugal; A. Madrigal, UK
- Adoptive T cell therapy and stem cell transplantation – impact of timing: J. Barrett, USA
- Innate T Cells: J. Kuball, The Netherlands
- HSV-TK cells adoptive therapy: F. Ciceri, Italy

The microbiota forum (2P)
Chair: M. Mohty, France
- Microbiota disruption and transplant outcome: TBA
- Modulation of chemotherapy activity by the microbiome: TBA
- Impact of the microbiome on acute GVHD: G. Hill, Australia

Access to innovations: the new challenges (3P)
Chairs: M. Abecasis, Portugal; D. Caballero, Spain
- Outcomes and benchmarking: the next frontier in HSCT: R. Duarte, Spain
- Modern drugs and cost-effectiveness: where are we going? J.L. Harousseau, France
- ATMP – the challenges: C. Chabannon, France
**How Do I ... Sessions**

Select the donor for my patient (HD1a): **E. Carreras**, Spain
Select the best haploidentical donor (HD1b): **D. Blaise**, France

Optimizing stem cell mobilization (HD2a): **C. Chabannon**, France
Optimizing the outcomes of cord blood stem cells (HD2b): **A. Ruggeri**, France

Managing severe aplastic anemia (HD3a): **L. Yañez**, Spain
Managing pure red cell aplasia (HD3b): **A. Tichelli**, Switzerland

Diagnosis and management of toxoplasmosis and pneumocystis jiuroveci (HD4a): **R. de la Cámara**, Spain
Diagnosis and management Listeriosis and Nocardiosis (HD4b): **E. Brissot**, France

**Meet the Expert Sessions**

Choice of the donor in haplo transplants (MTE1): **D. Blaise**, France
Management of steroid-refractory acute GVHD (MTE2): **E. Holler**, Germany
Management of liver dysfunction after transplant (MTE3): **T. Ruutu**, Finland
Transplant indications in CML (MTE4): **M. Abecasis**, Portugal
Maintenance therapy in Hodgkin disease (MTE5): **A. Sureda**, Spain
Options in refractory ALL in adults (MTE6): **S. Giebel**, Poland
Allogeneic transplantation for pediatric ALL (MTE7): **C. Peters**, Austria
Second allo-HSCT (MTE8): **F. Baron**, Belgium
HSCT for primary immunodeficiencies – how and when? (MTE9): **A. Genenery**, UK
Autologous transplant for scleroderma (MTE10): **D. Farge**, France
Treatment of Richter syndrome (MTE12): **P. Dreger**, Germany
Autologous HCT in amyloidosis (MTE13): **M. Rovira**, Spain
Immune cytopenias after HSCT (MTE14): **J. Passweg**, Switzerland
Transplant in myelofibrosis (MTE15): **N. Kröger**, Germany
Allogeneic transplantation in the elderly (MTE16): **G. Basak**, Poland
How I treat relapse after allogeneic SCT in children (MTE17): **P. Bader**, Germany
How to write a good manuscript, abstract or grant (MTE18): **H. Lazarus**, USA

**Special Sessions**

**Social Media session**

Chairs: **M. Mohty**, France; **N. Majhail**, USA
- Basic guidance and tips on how to use Twitter at a medical conference: **N. Majhail**, USA
- Case study on how the use of Twitter and other social media platforms is an asset to grow your own career: **K. Ghanem**, Lebanon

Panel discussion: Focusing on how hematologists and other HCPs can appropriately interact with patients on Twitter while maintaining privacy and ensuring ethical standards
Moderator: **N. Majhail**, USA
Panelists:
- **M. Mohty**, France
- **J. Boelens**, The Netherlands
- **M.A. Perales**, USA
- **C. Chmielewski**, USA

**How to get published?**

Session leaders:
- **J.V. Melo**, Australia
- **H. Lazarus**, USA
- **M Mohty**, France
Joint Sessions

EBMT global collaborations: East and West raising the bar together
Chairs: M. Mohty, France; N.C. Gorin, France; M. Abecasis, Portugal
- The sickle cell connection: B. Simões, Brazil
- Dynamics of HSCT in Latin America: G. Jaimovich, Argentina
- Collaboration among HCT societies/outcome registries – Asia-Pacific perspectives: S. Okamoto, Japan
- Biological characteristics of leukemia relapse after hematopoietic stem cell transplantation and immunotherapy: H. Huang, China

Cell Therapy Day

Session 1: Donor recruitment & Donation
Chairs: J. Halter, Switzerland; H. Trindade, Portugal
- Streamlining the search for related and unrelated donors: C. Lemarié, France
- Choosing wisely. Criteria to help in identifying the best available haplo-identical donor: F. Malard, France
- Off-label use of plerixafor in healthy donors: N. Worel, Austria

Session 2: Cell procurement & processing
Chairs: S. Roncon, Portugal; P. Perseghin, Italy
- Impact of apheresis collections on subsequent manufacturing of immunocellular products: A. Bersenev, USA
- New cryoprotectants – focusing on haematopoietic stem cell products: J. Dyrendom Svalgaard, Denmark
- Manufacturing of T-cells with anti-infectious activities (ADV, CMV, EBV) by an academic facility serving French transplant programs: an illustration of the hospital exemption: D. Bensoussan, France

Session 3: Joint EBMT - CARAT Session
Chair: C. Chabannon, France
- Quality vs quantity: what’s more important in CAR T-cells? A. Bondanza, Italy
- CARAT: Enabling technologies for CAR therapies: A. Kaiser, Germany
- Balancing safety and efficacy of CAR T-cells: G. Dotti, USA

Session 4: The EBMT Legal and Regulatory Affairs Committee special session
Chairs: J. Kuball, The Netherlands; R. Piteira, Spain & C. Bollard, USA
- Presentation of the EBMT LRAC: E. McGrath, Spain
- The EuroGTP II project: E. Trias, Spain
- How can we facilitate the delivery of advanced therapies to patients? M. Papadaki, UK

Paediatrics Day

Current Transplant Concepts in Children with AML (PDWP Session)
Chairs: P. Bader, Germany; J.-H. Dalle, France
- Indications and strategies for transplant in CR1 and CR2: F. Locatelli, Italy
- Current transplant approaches in children with AML in France: J.H-Dalle, France
- Is there an optimal conditioning regimen? M. Sauer, Germany
- Supportive Care and Complication: Results of the workshop for Supportive Care of PDWP: M. Ifversen, Denmark

Panel Discussion: Qupo vadis – Transplant in children with AML
Panelists:
- P. Bader, Germany
- B. Gibson, UK

Paediatric Educational Session: Acute lymphoblastic Leukemia – Detection and Prevention of Relapse
Chairs: X. Duarte, Portugal; K. Vettenranta
- Detection of impending relapse in children with leukemia after allo SCT: P. Bader, Germany
- Strategies to prevent relapse: from DLI to monoclonal antibodies: A. Balduzzi, Italy
- Cellular therapy with CAR-T-cells to prevent relapsed ALL: P. Amrolia, UK
Psy Day

Psy 1: Welcome

Psy 2: Opening
Chairs: M. Abecasis, Portugal; N. Miranda, Portugal; A. Ribeiro, Portugal & C. Nave, Portugal
  o Introduction: S. Moreira, Portugal

Psy 3: Keynote Opening Lecture
Chair: S. Moreira, Portugal
  o Patient-Centered Care: A. Barata, Spain

Psy 4: Psychosocial Support - Part One - To Patient
Chair: A. Barata, Spain
  o Psychological Evaluation of Patients Undergoing Bone Marrow Transplantation: S. Almeida, Portugal
  o Evaluation of an Exercise Intervention to Improve Cognition After Allogeneic Stem Cell Transplantation - The CaSpo Study: A. Scherwath, Germany

Psy 5: Psychosocial Support - Part Two - To Family
Chair: A. Scherwath, Germany
  o Psychosocial Needs of the Caregivers: A. Ribeiro, Portugal
  o GACIDHO: Support Group to the Informal Caregivers of the Hemato-Oncologic Patient: L. Calado, Portugal
  o The emotional impact of donating bone marrow to a sibling during adolescence: J. Elfer, UK

Psy 6: Psychosocial Support - Part Three - To Staff
Chair: A. Polomeni, France
  o A Psychological View of the Bone Marrow Transplant Team: F. Barbosa, Portugal
  o Helping Our Colleagues do What They Like Best: The UK Experience of Psychological Skills Training and Supervision for Nurse Specialists: A. King, UK

Psy 7: Keynote Closing Lecture
Chair: F. Schulz-Kindermann, Germany
  o Teams’ difficulties in HSCT setting – psychological and ethical issues: A. Polomeni, France

Working Party Sessions

Complications and Quality of Life (CQLWP) Session
Chairs: G. Basak, Poland; Z. Peric, Croatia
  o Introduction to WP and its activities: G. Basak, Poland
  o Complications of haploidentical HCT with posttransplant cyclophosphamide - prospective non-interventional study: G. Basak, Poland
  o Schistocyte quantification for the diagnosis of transplant-associated microangiopathy (TAM): I. Moiseev, Russia
  o Incidence, severity, management and outcome of SOS/VOD after alloHCT - prospective non-interventional study: T. Ruutu, Finland
  o Association between pre-HCT uric acid concentration and GvHD - prospective non-interventional study: O. Penack, Germany
  o Impact of ATG on outcome of patients after RIC for allogeneic HCT - retrospective study: H. Greinix, Austria
  o Autoimmune complications of alloHCT - EBMT survey: K. Hashaishi, UK
  o Investigation and management of bone density after HCT – EBMT survey: TBA
  o Outcome of patients with secondary malignancies after HCT - retrospective study: A. Tichelli, Switzerland

Acute Leukemia (ALWP) Session: Immunotherapy for prevention and treatment relapse after SCT in Acute Myeloid Leukemia
Chairs: A, Nagler, Israel, S. Giebel, Poland & C. Schmid, Germany
  o Opening Comments: A. Nagler, Israel
  o Pathogenesis of leukemic relapse post Allo: J. Sierra, Spain
  o Novel strategies to activate NK cells and make them antigen-specific: J. Miller, USA
  o Unmanipulated donor T-cells – clinical outcome: C. Schmid, Germany
  o Immunecheckpoint inhibitors: A. Nagler, Israel
Treating AML with CAR-T cell and antibodies: G. Ehninger, Germany
Summary and Questions: A. Nagler, Israel

Autoimmune Diseases (ADWP) Session
Chairs: J. Snowden, UK; T. Alexander, Germany
- Summary of ADWP database activity: J. Snowden, UK; T. Alexander, Germany
- HSCT for systemic sclerosis – patient selection and future perspectives: D. Farge, France
- Mesenchymal stem cells open a window on cell therapy in systemic sclerosis: N. del Papa, Italy
- Polish experience of HSCT for autoimmune diseases: E. Snarski, Poland
- Russian experience in HSCT for autoimmune diseases: K. Kirgizov, Russia
- Chinese experience in autologous HSCT with special focus on systemic lupus erythematosus: TBA

Lymphoma (LWP) Session
Chair: S. Montoto, UK
Introduction: S. Montoto, UK
Highlights of the LWP activity: S. Robinson, UK
LWP Educational Course 2018: A. Sureda, Spain
Presentation of the Jian-jian Luan award winner: S. Montoto, UK
Lecture of the Jian-jian Luan award abstract: TBA
LWP keynote debate: Should we choose a halpo over a 10/10 donor in NHL?
  - No: S. Montoto, UK
  - Yes: N. Schmitz
  - Discussion: L. Castagna, Italy
Concluding remarks: S. Montoto, UK & S. Robinson, UK